SEP093-701: Efficacy and Safety of Eslicarbazepine Acetate as First Add-on to Levetiracetam or Lamotrigine Monotherapy or as Later Adjunctive Treatment for Subjects with Uncontrolled Partial-onset Seizures: A Multicenter, Open-label, Non- randomized Trial

Grants and Contracts Details

StatusFinished
Effective start/end date1/26/189/5/18

Funding

  • Sunovion Pharmaceuticals Incorporated: $6,911.00